Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMU-838 added to standard of care for hospitalized patients with COVID-19
2020-001264-28Phase 2Completed
- Sponsor
- Immunic Therapeutics
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Vidofludimus calcium + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Proportion of patients without any need for invasive ventilation until end of study. Started Apr 2020; status: completed.
02
Drugs
vidofludimus calcium
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001264-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001264-28.